Share on LinkedInShare on LinkedIn

ARTICLE · 31 MAY 2022

New Court Proceedings (May 2022)

Smart & Biggar
Explore more from Smart & Biggar

Taro Pharmaceuticals v Biogen and Acorda Therapeutics.

CanadaLitigation, Mediation & Arbitration
Nancy Pei
Nancy Pei
Author LinkedIn connections

Section 8 Proceedings:

  • FAMPYRA (fampridine): Taro Pharmaceuticals v Biogen and Acorda Therapeutics

PM(NOC) Proceedings:

  • TRINTELLIX (vortioxetine): Lundbeck v Sandoz Canada
  • ODEFSEY (emtricitabine / rilpivirine / tenofovir alafenamide): Janssen Pharmaceutical v Apotex
  • DESCOVY (tenofovir alafenamide hemifurate): Gilead Sciences v Apotex
  • ODEFSEY (emtricitabine / rilpivirine / tenofovir alafenamide): Gilead Sciences v Apotex

For complete details about these proceedings, click here.

The preceding is intended as a timely update on Canadian intellectual property and technology law. The content is informational only and does not constitute legal or professional advice. To obtain such advice, please communicate with our offices directly.

The preceding is intended as a timely update on Canadian intellectual property and technology law. The content is informational only and does not constitute legal or professional advice. To obtain such advice, please communicate with our offices directly.

Related Articles

Legal Intelligence Newsletters

Read more about

Related Comparative Guides

See more popular content from

Article

Ontario’s New AI Rules: What Lawyers And Expert Witnesses Need To Know

Ontario's Rules of Civil Procedure now include strict amendments requiring lawyers and expert witnesses to certify the authenticity of every citation and authority used in court materials. These new anti-hallucination provisions impose significant penalties for presenting AI-generated fabricated authorities, fundamentally shifting accountability for artificial intelligence use in litigation.
CanadaLitigation, Mediation & Arbitration
Soloway Wright
Soloway Wright
Article

The Coldcard Exploit: Why Victims May Have Two Routes To Recovery

A five-year-old firmware defect in Coldcard hardware wallets has enabled attackers to systematically drain an estimated $116 million in Bitcoin from over 5,200 victims since July 2026. This unprecedented exploit raises critical questions about manufacturer liability and creates two distinct legal pathways for recovery: blockchain tracing against the perpetrators and potential litigation against Canadian manufacturer Coinkite for product defects that undermined the fundamental security promise of devices mar
CanadaLitigation, Mediation & Arbitration
WeirFoulds LLP
WeirFoulds LLP
Article

Do Canadian Manufacturers Owe A Duty To Develop Safer Alternatives?

The British Columbia Court of Appeal has left open the possibility that pharmaceutical manufacturers may owe a duty of care to develop safer alternatives to their existing products, even when those products are properly approved and labeled. This decision in Gilead Sciences, Inc. v. I.F. contrasts sharply with a recent California Supreme Court ruling that rejected such a "duty to innovate," potentially setting Canada on a divergent path in product liability law.
CanadaLitigation, Mediation & Arbitration
Torys
Torys
Article

Spoliation: What Litigants Need To Know About Preserving Evidence

The Supreme Court of Canada has clarified the legal test for spoliation, establishing a four-part framework that litigants must understand when preserving evidence. This doctrine, rooted in ancient Roman law, creates a mandatory presumption against parties who intentionally destroy or suppress relevant evidence, with courts now empowered to impose severe but proportionate remedies based on the magnitude of the misconduct.
CanadaLitigation, Mediation & Arbitration
Alexander Holburn Beaudin + Lang LLP
Alexander Holburn Beaudin + Lang LLP
Article

Pharmaceutical And Life Sciences Sector Task Force Submits Final Report To The Ministers Of Health And Industry

The Pharmaceutical and Life Sciences Sector Task Force has released its final report addressing Canada's challenges in medication access, regulatory processes, and life sciences competitiveness. The report examines structural issues including lengthy reimbursement pathways, underperforming clinical trial environments, and erosion of domestic investment, while proposing 39 recommendation areas to strengthen Canada's health sovereignty and industrial strategy.
CanadaFood, Drugs, Healthcare, Life Sciences
Smart & Biggar
Smart & Biggar
Article

A KTEP Ahead: Canada's New Mechanism For Advanced Examination Of Patent Applications

For a Canadian patent application to be examined, an applicant must file a request for examination with the Canadian Intellectual Property Office (CIPO). In most cases, the order in which applications are examined is based on the order that the requests for examination are received. An applicant may be able to accelerate examination of their patent application through several existing mechanisms, including advancing examination via special order, accelerating examination of applications related to green technology, and the Patent Prosecution Highway (PPH).
CanadaIntellectual Property
Smart & Biggar
Smart & Biggar